- Home
- STHO vs CAPR Comparison
STHO vs CAPR Comparison
Compare STHO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CAPR
- Stock Information
- Founded
- STHO N/A
- CAPR 2005
- Country
- STHO United States
- CAPR United States
- Employees
- STHO N/A
- CAPR N/A
- Industry
- STHO Real Estate
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- CAPR Health Care
- Exchange
- STHO Nasdaq
- CAPR Nasdaq
- Market Cap
- STHO 173.3M
- CAPR 148.1M
- IPO Year
- STHO N/A
- CAPR N/A
- Fundamental
- Price
- STHO $13.77
- CAPR $4.43
- Analyst Decision
- STHO
- CAPR Strong Buy
- Analyst Count
- STHO 0
- CAPR 4
- Target Price
- STHO N/A
- CAPR $21.75
- AVG Volume (30 Days)
- STHO 30.5K
- CAPR 214.1K
- Earning Date
- STHO 08-06-2024
- CAPR 08-07-2024
- Dividend Yield
- STHO N/A
- CAPR N/A
- EPS Growth
- STHO N/A
- CAPR N/A
- EPS
- STHO N/A
- CAPR N/A
- Revenue
- STHO $136,773,000.00
- CAPR $27,152,218.00
- Revenue This Year
- STHO N/A
- CAPR N/A
- Revenue Next Year
- STHO N/A
- CAPR $223.32
- P/E Ratio
- STHO N/A
- CAPR N/A
- Revenue Growth
- STHO 38.53
- CAPR 187.15
- 52 Week Low
- STHO $10.76
- CAPR $2.68
- 52 Week High
- STHO $15.31
- CAPR $7.28
- Technical
- Relative Strength Index (RSI)
- STHO 60.91
- CAPR 58.23
- Support Level
- STHO $12.69
- CAPR $4.05
- Resistance Level
- STHO $13.07
- CAPR $4.33
- Average True Range (ATR)
- STHO 0.29
- CAPR 0.23
- MACD
- STHO 0.00
- CAPR 0.02
- Stochastic Oscillator
- STHO 87.75
- CAPR 70.88
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.